La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Karolinska Development Gestion

Gestion contrôle des critères 3/4

Le PDG Karolinska Development's est Viktor Drvota, nommé en Jun2017, a un mandat de 7.17 ans. La rémunération annuelle totale est SEK 4.73M, composée du salaire de 62.9% et des bonus 37.1%, y compris les actions et options de la société. détient directement 0.078% des actions de la société, d'une valeur de SEK 293.98K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.2 ans et 3.5 ans.

Informations clés

Viktor Drvota

Directeur général

SEK 4.7m

Rémunération totale

Pourcentage du salaire du PDG	62.9%
Durée du mandat du directeur général	7.2yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	4.2yrs
Durée moyenne du mandat des membres du conseil d'administration	3.5yrs

Mises à jour récentes de la gestion

Recent updates

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Apr 27

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

Feb 08

Analyse de la rémunération des PDG

Comment la rémunération de Viktor Drvota a-t-elle évolué par rapport aux bénéfices de Karolinska Development?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	SEK 34m
Dec 31 2023	SEK 5m	SEK 3m	SEK 5m
Sep 30 2023	n/a	n/a	SEK 17m
Jun 30 2023	n/a	n/a	-SEK 41m
Mar 31 2023	n/a	n/a	-SEK 87m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 88m
Sep 30 2022	n/a	n/a	-SEK 118m
Jun 30 2022	n/a	n/a	-SEK 72m
Mar 31 2022	n/a	n/a	SEK 166m
Dec 31 2021	SEK 5m	SEK 3m	SEK 171m
Sep 30 2021	n/a	n/a	SEK 276m
Jun 30 2021	n/a	n/a	SEK 108m
Mar 31 2021	n/a	n/a	-SEK 106m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 207m
Sep 30 2020	n/a	n/a	SEK 35m
Jun 30 2020	n/a	n/a	SEK 190m
Mar 31 2020	n/a	n/a	SEK 195m
Dec 31 2019	SEK 6m	SEK 3m	SEK 303m
Sep 30 2019	n/a	n/a	-SEK 11m
Jun 30 2019	n/a	n/a	SEK 8m
Mar 31 2019	n/a	n/a	SEK 32m
Dec 31 2018	SEK 5m	SEK 3m	SEK 31m
Sep 30 2018	n/a	n/a	SEK 48m
Jun 30 2018	n/a	n/a	SEK 238m
Mar 31 2018	n/a	n/a	SEK 185m
Dec 31 2017	SEK 5m	SEK 1m	SEK 180m

Rémunération vs marché: La rémunération totale de Viktor ($USD 458.81K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 278.75K ).

Rémunération et revenus: La rémunération de Viktor a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Viktor Drvota (59 yo)

7.2yrs

Titularisation

SEK 4,733,000

Compensation

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Viktor Drvota	Chief Executive Officer	7.2yrs	SEK 4.73m	0.078% SEK 288.5k
Hans Toll	Chief Financial Officer	1.8yrs	pas de données	0.013% SEK 48.1k
Per Aniansson	Investment Director	3.4yrs	pas de données	0.059% SEK 219.9k
Eva Montgomerie	Head of Accounting	10.8yrs	pas de données	0.012% SEK 45.5k
John Öhd	Chief Scientific Officer & Venture Partner	4.2yrs	pas de données	pas de données
Johan Dighed	Chief Legal Officer & Deputy CEO	4.3yrs	pas de données	0.15% SEK 549.9k
Yan Cheng	President of Asia	7.1yrs	pas de données	0.0093% SEK 34.4k
Tse Ping	Senior Strategic Advisor	no data	pas de données	pas de données
Linda Spahiu	Investment Manager	no data	pas de données	0.0037% SEK 13.8k
Mikaela Sörman	Investment Manager	no data	pas de données	0.0037% SEK 13.8k

4.2yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de KDEV est considérée comme expérimentée (ancienneté moyenne 4.2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Hans Wigzell	Chairman	less than a year	SEK 500.00k	pas de données
Anna Lefevre Skjoldebrand	Independent Director	3.5yrs	SEK 200.00k	pas de données
Y. Y. Tse	Director	7.6yrs	pas de données	pas de données
Ben Toogood	Director	3.5yrs	SEK 178.00k	0.024% SEK 87.9k
Philip Duong	Director	2.6yrs	SEK 200.00k	pas de données

3.5yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de KDEV sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).

Karolinska Development Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought kr81k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Recent updates

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Price target decreased to kr5.40

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Price target increased to kr7.90

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

New 90-day low: kr1.59

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: kr1.61

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

New 90-day low: kr1.80

Investor sentiment deteriorated over the past week

New 90-day low: kr2.17

New 90-day low: kr2.31

New 90-day low: kr2.60

New 90-day low: kr2.61